Veracyte, Inc.
Financials
Valuation Metrics
Veracyte, Inc.'s Market Cap is $3.18B. At end of 2025 it was $3.33B. Ranked #1679 of 3,121 in US market (top 54%), #600 of 1,463 on NASDAQ (top 41%), #100 of 205 in Health Care Equipment & Services (top 49%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.18B | US#1,679/3,121 Sec#100/205 |
| Revenue | $562M | US#2,217/3,121 Sec#140/205 |
| Net Income | $114M | US#1,570/3,121 Sec#78/205 |
| Total Assets | $1.49B | US#2,272/3,121 Sec#115/205 |
| Net Assets | $1.39B | US#1,531/3,121 Sec#79/205 |
| Employees | 755 | US#2,106/3,121 Sec#148/205 |
| Value | ||
| P/E | 27.74x | US#1,523/3,121 Sec#57/205 |
| P/B | 2.29x | US#1,447/3,121 Sec#70/205 |
| PEG | 0.08x | US#189/3,121 Sec#7/205 |
| P/S | 5.65x | US#2,402/3,121 Sec#155/205 |
| EV/EBITDA | 22.47x | US#2,021/3,121 Sec#96/205 |
| FCF Yield | 5.21% | US#1,390/3,121 Sec#66/205 |
| Profitability | ||
| ROE | 8.25% | US#1,569/3,121 Sec#77/205 |
| ROA | 7.70% | US#690/3,121 Sec#41/205 |
| Op. Margin | 17.03% | US#1,092/3,121 Sec#35/205 |
| Revenue Growth | 17.28% | US#802/3,121 Sec#52/205 |
| Earnings Growth | 334.72% | US#103/3,121 Sec#6/205 |
| Financial Health | ||
| Debt Ratio | 7.06% | US#66/3,121 Sec#4/205 |
| Total Debt | $40M | US#2,645/3,121 Sec#156/205 |
| FCF | $165M | US#1,493/3,121 Sec#84/205 |
| Cash | $300M | US#1,417/3,121 Sec#79/205 |
| Current Ratio | 9.16x | US#286/3,121 Sec#13/205 |
| Net Debt/EBITDA | -2.00x | US#172/3,121 Sec#14/205 |
| Performance | ||
| 1Y Return | 19.76% | US#975/3,121 Sec#77/205 |
| 1M Return | -5.68% | US#980/3,121 Sec#100/205 |
| From 52W High | -34.67% | US#2,225/3,121 Sec#148/205 |
| 1Y MDD | -39.23% | US#1,981/3,121 Sec#111/205 |
| Trading | ||
| Volume | 2,524,675 shares | US#1,119/3,121 Sec#68/205 |
| Trading Value | $101M | US#1,186/3,121 Sec#87/205 |
| Per Share | ||
| EPS | $1.43 | US#1,534/3,121 Sec#79/205 |
| BPS | $17.40 | US#1,387/3,121 Sec#77/205 |
Company Info
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.